- 全部删除
您的购物车当前为空
Nebivolol hydrochloride (R 065824 hydrochloride) 是一种β1-肾上腺素受体选择性抑制剂,IC50为0.8 nM。

Nebivolol hydrochloride (R 065824 hydrochloride) 是一种β1-肾上腺素受体选择性抑制剂,IC50为0.8 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | ¥ 263 | In stock | |
| 25 mg | ¥ 477 | In stock | |
| 50 mg | ¥ 828 | In stock | |
| 100 mg | ¥ 1,330 | In stock | |
| 200 mg | ¥ 1,980 | In stock | |
| 500 mg | ¥ 3,990 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 178 | In stock |
Nebivolol hydrochloride 相关产品
| 产品描述 | Nebivolol hydrochloride (R 065824 hydrochloride) is a cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients. |
| 靶点活性 | β1-adrenoceptor:0.8 nM |
| 体外活性 | Nebivolol处理患心肌梗塞大鼠,少量降低平均血压.开始静脉注射Nebivolol 10分钟,然后再口服处理患有心肌梗塞的大鼠,可以降低心肌凋亡. |
| 体内活性 | Nebivolol可以降低冠状动脉平滑肌细胞(haCSMCs)及内皮细胞(haECs)增殖,这种作用存在浓度和时间依赖性。Nebivolol在制备兔肺膜时,作用于beta 1-肾上腺素受体位点具有高亲和性和高度选择性。Nebivolol处理haCSMCs7天,明显抑制细胞增殖(IC50:6.1 μM)。Nebivolol处理haCSMCs 48小时,细胞凋亡率23%,且降低S期细胞数量。 |
| 细胞实验 | Cells are exposed to different concentrations of Nebivolol (10-7~10-5 M) for 1, 2, 4, 7 and 14 days. Cell proliferation is analyzed by bromodeoxyuridine (BrdU) incorporation, and cell apoptosis is detected by PI or annexin V staining.(Only for Reference) |
| 别名 | 盐酸奈必洛尔, R-65824, R 065824 hydrochloride, Nebivolol HCl |
| 分子量 | 441.90 |
| 分子式 | C22H25F2NO4·HCl |
| CAS No. | 152520-56-4 |
| Smiles | Cl.OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1 |
| 密度 | no data available |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| 溶解度信息 | Ethanol: 4.40 mg/mL (9.96 mM), Sonication is recommended. DMSO: 60 mg/mL (135.78 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
评论内容